Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Monday's Bonus Story 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go hand in hand. But if you’re considering the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage and have no commercially available drugs or therapeutics. That status typically means negative earnings and little to no revenue. Success often hinges on the outcome of a single clinical-stage program. A new generation of AI is expected to come online in early 2026, and some analysts believe its impact could extend far beyond technology or markets.
In a recent broadcast, one researcher explains why this shift could accelerate innovation across healthcare, productivity, and the economy — and outlines a small group of companies he believes may benefit most as the transition unfolds. Watch the full broadcast here Even when a product advances through trials, profitability can be years away. Only after reaching that milestone do companies usually attract the analyst coverage and institutional capital that meaningfully move valuations. Still, getting in on the right medical stock early can pay off handsomely. In an instant, an investor could realize 3x, 5x, or even 10x returns — while other names may never pan out. For many penny-stock investors, spreading a lump sum across multiple biotech companies is a common way to manage the odds. If it’s a numbers game, diversification helps. With that in mind, here are two small-cap biotech stocks that carry significant risk but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in this sector, Mainz has a commercially available product: ColoAlert, the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany’s digital-health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is meaningful. The company is also developing a noninvasive, blood-based screening test for early detection of pancreatic cancer and reported positive topline results in October. Commercial approval for that program, however, remains years away. The risks are real. ColoAlert is not yet available in the United States, and despite early European sales and plans to expand into South America, revenue is still minimal. Reflecting the financial challenges, the company included “going concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed filed a $150 million mixed shelf offering. For now, that filing helps keep the MYNZ share price above $1 and out of immediate delisting danger. Mainz is racing to generate meaningful revenue. If it succeeds, even a modest early position could deliver a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is a micro-cap biotech pursuing a potentially disruptive antiviral approach — and it carries the financial risks typical of speculative small caps. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These candidates are designed to mimic human cell surfaces and lure viruses to bind with them, effectively neutralizing the pathogens before they infect real cells. If validated in human trials, this approach could represent a new method for treating infectious diseases. NanoViricides’ pipeline targets shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced, with encouraging preclinical data suggesting strong antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on fresh capital to continue development. Recent filings show limited cash on hand, and investors should expect potential dilution. Still, if one candidate advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC could be a genuine moonshot in the antiviral space.
| 
